That ressource is reserved for health professionals

This space contains information on medical devices, the use of which is reserved for healthcare professionals. In application of the law of December 29, 2011 relating to the strengthening of health security, I certify that I am a health professional and therefore be authorized to access this information.

I am a healthcare professional


Close window if you are not a healthcare professional


Close menu



Promise Proteomics (Fr) is collaborating with GERCOR in the NIPISAFE study aimed at identifying a new treatment regimen for patients with colorectal cancer.

Therapeutic Drug Monitoring solutions developed by Grenoble-based MedTech Promise Proteomics are being used in the NIPISAFE clinical study, a phase 2 clinical study sponsored by GERCOR and whose principal investigator is Dr Romain Cohen (Saint Antoine Hospital, Paris). The main objective of NIPISAFE is to identify a new immunotherapy regimen, more effective and less toxic, for selected colorectal cancer patients. As part of this study, several parameters are being monitored including the concentration of the two co -injected immunotherapies, Nivolumab and Ipilimumab. This quantification assay is carried out in the pharmacology laboratory at Henri Mondor hospital, headed by Dr Anne Hulin, using mAbXmise Oncology kits, developed by the company Promise Proteomics.


“We were fortunate to be able to collaborate very early on with health professionals, like Anne Hulin, who were interested in our technology. It’s a source of great pride to see our solutions at the heart of clinical studies such as NIPISAFE, which will undoubtedly lead to advances in the fight against cancer” explains Dorothée Lebert, Scientific Director of Promise Proteomics.


Promise Proteomics’ contribution to the NIPISAFE study also involves the evaluation of the immune response to the combined treatment Nivolumab and Ipilimumab. Among the parameters monitored, this involves measuring the concentration of anti-drug antibodies, likely to weaken or inhibit the expected therapeutic effect. This brand new technological approach to monitoring anti-drug antibodies by mass spectrometry was specifically developed by Promise Proteomics for this project, capitalizing on its experience in monitoring inflammatory diseases.


About Promise

The ambition of Promise Proteomics and its mAbXmise range is to adjust the dose for each patient, enabling a new advance in the personalized management of pathologies eligible for biotherapies. This MedTech, 100% owned by the Aguettant group, has unique know-how in the production of internal standards for protein assays and recognized expertise for mass spectrometry assay methods. Promise Proteomics now offers a mAbXmise range, comprised of 7 kits (CE-IVD status obtained or in the process of being obtained), allowing the dosage of 20 therapeutic antibodies used routinely in various pathologies.



Created in 1997, GERCOR is a non-profit organization whose mission is to improve treatments for cancer patient (solid tumors) through innovative and multidisciplinary clinical research. GERCOR is a promoter of clinical trials (Ph I to III) and strives to conduct them in complete independence. It relies on a national network of 300 centers (university hospitals, cancer centers, general hospitals and private centers), as well as collaborations with other academic groups in France and is internationally coordinated by an operational team certified by the National Cancer Institute (INCA) and the National League Against Cancer.